α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …

Abstract Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy
approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic …

The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …

Abstract Background The European directive on basic safety standards (Council directive
2013/59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical …

Purpose To investigate the improvement of prognostication of active bone metastatic burden
by discriminating bone metastases from degenerative changes in hot foci, using skeletal …

Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent
and local radiation selectively to cancer cells as well as the tumor microenvironment and …

The current mainstay of treatment in metastatic prostate cancer is based on hormonal
manipulations. Standard androgen deprivation therapy and novel androgen axis drugs are …

Targeted alpha therapy (TAT) can deliver high localized burden of radiation selectively to
cancer cells as well as the tumor microenvironment, while minimizing toxicity to normal …

Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …